FGF23 and X-linked hypophosphatemia: We next explored the impact of the FGF23-mAb treatment in Hyp mice to assess whether the positive outcomes found on alveolar bone and dental features in two adult patients with XLH treated with burosumab was also found in the mouse model of the disorder (Fig. 1).